Core Viewpoint - The company is set to present clinical data for ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st European Association for the Study of Diabetes (EASD) annual meeting in Vienna, Austria, highlighting its potential as a differentiated treatment for obesity [1] Company Summary - The CEO of the company, Dr. Wu Jinzi, expressed optimism about the clinical efficacy and safety data for ASC30, suggesting it could become a unique solution for obesity treatment [1] - ASC30 is a new chemical entity (NCE) with both oral and subcutaneous administration capabilities, supported by patent protection in the U.S. and globally until 2044, excluding any patent extensions [1]

Core Insights - The company announced the completion of participant enrollment for the 13-week Phase IIa study of ASC30, a small molecule oral GLP-1 receptor agonist for obesity treatment, with 125 subjects enrolled [1][2] - The CEO expressed optimism about ASC30's potential as a differentiated therapy for obesity, highlighting the urgent need for more treatment options in the market [1] - The Phase IIa study aims to evaluate the efficacy, safety, and tolerability of ASC30 in obese subjects and overweight subjects with at least one weight-related comorbidity [1] Study Details - The study is randomized, double-blind, placebo-controlled, and multi-center, focusing on two oral formulations of ASC30 [1] - The primary endpoint is the percentage change in average weight from baseline at week 13 [1] - Both formulations will start at a dose of 1 mg, with weekly titrations to reach target maintenance doses of 20 mg and 40 mg for formulation 1, and 20 mg, 40 mg, and 60 mg for formulation 2 [1] Drug Characteristics - ASC30 is the first and only small molecule GLP-1R biased agonist that can be administered both orally and via monthly subcutaneous injection [2] - The drug is a new chemical entity (NCE) with patent protection in the U.S. and globally until 2044, excluding any patent extensions [2] - Formulation 2 has shown a smoother pharmacokinetic profile compared to formulation 1 in previous studies [2]